285 related articles for article (PubMed ID: 15919502)
1. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation.
Forgacs B; Merhav HJ; Lappin J; Mieles L
Transplant Proc; 2005 May; 37(4):1912-4. PubMed ID: 15919502
[TBL] [Abstract][Full Text] [Related]
2. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
[TBL] [Abstract][Full Text] [Related]
4. Indications and management of everolimus after liver transplantation.
Bilbao I; Sapisochin G; Dopazo C; Lazaro JL; Pou L; Castells L; Caralt M; Blanco L; Gantxegi A; Margarit C; Charco R
Transplant Proc; 2009; 41(6):2172-6. PubMed ID: 19715864
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
[TBL] [Abstract][Full Text] [Related]
6. A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation.
Zaghla H; Selby RR; Chan LS; Kahn JA; Donovan JA; Jabbour N; Genyk Y; Mateo R; Gagandeep S; Sher LS; Ramicone E; Fong TL
Aliment Pharmacol Ther; 2006 Feb; 23(4):513-20. PubMed ID: 16441472
[TBL] [Abstract][Full Text] [Related]
7. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation.
Yang YJ; Li LX; He Q; Fan H; Jin ZK; Lang R; Kou JT; Li P; Xie DH; Chen DZ
Hepatobiliary Pancreat Dis Int; 2007 Aug; 6(4):376-8. PubMed ID: 17690032
[TBL] [Abstract][Full Text] [Related]
9. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
11. Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus.
Casas-Melley AT; Falkenstein KP; Flynn LM; Ziegler VL; Dunn SP
Pediatr Transplant; 2004 Aug; 8(4):362-6. PubMed ID: 15265163
[TBL] [Abstract][Full Text] [Related]
12. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
[TBL] [Abstract][Full Text] [Related]
13. Conversion to everolimus in maintenance patients--current clinical strategies.
Pohanka E
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii24-9. PubMed ID: 16815853
[TBL] [Abstract][Full Text] [Related]
14. Central pontine myelinolysis: a case report and clinical-pathological review.
Cui R; Fayek S; Rand EB; Feygin T; Khrichenko D; Shaked A
Pediatr Transplant; 2012 Sep; 16(6):E251-6. PubMed ID: 22023701
[TBL] [Abstract][Full Text] [Related]
15. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients.
Balfour IC; Srun SW; Wood EG; Belsha CW; Marshall DL; Ferdman BR
J Heart Lung Transplant; 2006 May; 25(5):518-22. PubMed ID: 16678029
[TBL] [Abstract][Full Text] [Related]
16. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients.
Morard I; Dumortier J; Spahr L; Hadengue A; Majno P; Morel P; Mentha G; Giostra E
Liver Transpl; 2007 May; 13(5):658-64. PubMed ID: 17457887
[TBL] [Abstract][Full Text] [Related]
17. Possible therapeutic effect of lipid supplementation on neurological complications in liver transplant recipients.
Ide K; Ohdan H; Tahara H; Ishiyama K; Shishida M; Irei T; Ohira M; Tashiro H; Itamoto T; Asahara T
Transpl Int; 2007 Jul; 20(7):632-5. PubMed ID: 17442068
[TBL] [Abstract][Full Text] [Related]
18. The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation.
Arora-Gupta N; Davies P; McKiernan P; Kelly DA
Pediatr Transplant; 2004 Apr; 8(2):145-50. PubMed ID: 15049794
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction due to calcineurin inhibitors.
Di Benedetto F; Di Sandro S; De Ruvo N; Spaggiari M; Montalti R; Ballarin R; Cappelli G; Gerunda GE
J Clin Gastroenterol; 2009 Mar; 43(3):280-6. PubMed ID: 19057397
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
Kushwaha SS; Khalpey Z; Frantz RP; Rodeheffer RJ; Clavell AL; Daly RC; McGregor CG; Edwards BS
J Heart Lung Transplant; 2005 Dec; 24(12):2129-36. PubMed ID: 16364861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]